Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -142,568 | -120,587 | -89,270 | -73,476 | -62,917 |
| Depreciation Amortization | 623 | 1,878 | 2,657 | 2,596 | 3,504 |
| Accounts receivable | -26,952 | 80 | 30 | N/A | N/A |
| Accounts payable and accrued liabilities | 1,691 | 2,607 | 953 | -692 | -3,399 |
| Other Working Capital | 22,717 | 6,443 | 2,761 | 2,524 | -10,232 |
| Other Operating Activity | 40,243 | 14,237 | 23,042 | 13,379 | 17,971 |
| Operating Cash Flow | $-104,246 | $-95,342 | $-59,827 | $-55,669 | $-55,073 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -313,370 | -2,525 | -1,668 | -3,328 | -6,975 |
| Purchase Of Investment | -6,991 | -36,028 | -280,681 | -54,087 | N/A |
| Sale Of Investment | 213,435 | 157,445 | 208,650 | 1,000 | N/A |
| Purchase Sale Intangibles | -100 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -100 | -100 | -1,800 | 0 | 0 |
| Investing Cash Flow | $-107,026 | $118,792 | $-75,499 | $-56,415 | $-6,975 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 6,750 |
| Debt Repayment | -932 | -3,636 | -3,541 | -5,250 | -12,544 |
| Common Stock Issued | 5,292 | 200,797 | 1,649 | 139,004 | 236,323 |
| Other Financing Activity | -2,578 | -1,217 | -750 | 8,838 | -1,438 |
| Financing Cash Flow | $1,782 | $195,944 | $-2,642 | $142,592 | $229,091 |
| Beginning Cash Position | 283,476 | 64,082 | 202,050 | 171,542 | 4,499 |
| End Cash Position | 73,986 | 283,476 | 64,082 | 202,050 | 171,542 |
| Net Cash Flow | $-209,490 | $219,394 | $-137,968 | $30,508 | $167,043 |
| Free Cash Flow | |||||
| Operating Cash Flow | -104,246 | -95,342 | -59,827 | -55,669 | -55,073 |
| Capital Expenditure | -314,911 | -2,525 | -1,670 | -3,328 | -6,975 |
| Free Cash Flow | -419,157 | -97,867 | -61,497 | -58,997 | -62,048 |